Monensin

Monensin (Monensin A), an orally active antibiotic, is an ionophore that mediates Na+/H+ exchange. Monensin is a potent Wnt signaling inhibitor. Monensin causes a marked enlargement of the multivesicular bodies (MVBs) and regulates exosome secretion. Monensin can be used for bacterial, fungal, and parasitic infections research, and shows anticancer effects[1][2][3][4].

Product Specifications

CAS Number

[17090-79-8]

Product Name Alternative

Monensin A

UNSPSC

12352005

Target

Antibiotic; Apoptosis; Bacterial; Fungal; Na+/H+ Exchanger (NHE) ; Parasite; Wnt

Type

Natural Products

Related Pathways

Anti-infection; Apoptosis; Membrane Transporter/Ion Channel; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/monensin.html

Solubility

10 mM in DMSO

Smiles

C[C@]1([C@]2([H])O[C@@](CC2)([C@]3([H])O[C@]([C@@]4([H])O[C@](O)([C@@H](C[C@@H]4C)C)CO)([H])C[C@@H]3C)CC)O[C@@]5(CC1)O[C@]([C@@H]([C@H](C5)O)C)([H])[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O

Molecular Formula

C36H62O11

Molecular Weight

670.87

References & Citations

[1]Dayekh K, et al. Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors. Mol Cancer Ther. 2014 Nov;13 (11) :2559-71.|[2]Tumova L, et al. Monensin inhibits canonical Wnt signaling in human colorectal cancer cells and suppresses tumor growth in multiple intestinal neoplasia mice. Mol Cancer Ther. 2014 Apr;13 (4) :812-22. |[3]Youhua Huang, et al. Autophagy Participates in Lysosomal Vacuolation-Mediated Cell Death in RGNNV-Infected Cells. Front Microbiol. 2020 Apr 30:11:790. |[4]Ariel Savina, et al. Rab11 promotes docking and fusion of multivesicular bodies in a calcium-dependent manner. Traffic. 2005 Feb;6 (2) :131-43.